Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Oral vs Inpatient IV Antibiotics for Low-Risk Pediatric Febrile Neutropenia
NCT00107081Phase 3Terminated
- Sponsor
- Swiss Pediatric Oncology Group
- Start
- Jan 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ciprofloxacin and amoxicillin in febrile neutropenia (FN) (2 arms), sponsored by Swiss Pediatric Oncology Group. Primary endpoints: Safety: No serious medical complication due to infection and Efficacy: Response without rehospitalization or changing randomized antibiotics. Started Jan 2004; status: terminated.
02
Drugs
ciprofloxacinamoxicillin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00107081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107081.